The CosMx™ SMI and decoder probes are not offered and/or delivered to the Federal Republic of Germany for use in the Federal Republic of Germany for the detection of cellular RNA, messenger RNA, microRNA, ribosomal RNA and any combinations thereof in a method used in fluorescence in situ hybridization for detecting a plurality of analytes in a sample without the consent of the President and Fellows of Harvard College (Harvard Corporation) as owner of the German part of EP 2 794 928 B1. The use for the detection of cellular RNA, messenger RNA, microRNA, ribosomal RNA and any combinations thereof is prohibited without the consent of the President and Fellows of Harvard College (Harvard Corporation).
The CosMx™ SMI and decoder probes are not offered and/or delivered to the following UPC member states* for use in these countries for the detection of RNA in a method used for the detection of a plurality of analytes in a cell or tissue sample without the consent of the President and Fellows of Harvard College (Harvard Corporation) as owner of the Unitary Patent EP 4 108 782 B1. The use for the detection of RNA is prohibited without the consent of the President and Fellows of Harvard College (Harvard Corporation).
* Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Slovenia, Sweden
Helping Your Research
Human Single-Cell Spatial RNA Analysis
The CosMx Human Immuno-oncology Panel is optimized for cell typing of key immune and stromal cells and evaluation of immune infiltration and tumor microenvironments. Profile expression of 100 transcripts covering immune cells, their activities, and aspects of tumor biology relevant to IO therapies, and customize with up to ten of your own targets.
How it Works
The CosMx Human Immuno-oncology Panel for the CosMx Spatial Molecular Imager provides robust spatial single-cell analysis with an emphasis on key applications for immuno-oncology and cell typing of immune and stromal cells.
Robust Cell Typing
NK cells/CD8 and CD4 T cells/Treg cells/Neutrophils/Endothelial cells/Fibroblasts/Monocytic Dendritic Cells/Plasmacytoid Dendritic Cells/Monocytes/Plasmablasts/B cells
Immuno-oncology Physiological targets
Cytokine and chemokine signaling/immune checkpoints/inflammation/Antigen Presentation/Cell Cycle
100-plex format offers faster turnaround and lower overall cost than high-plex panels
Customize with up to ten targets of your own
Publications & Posters
Characterizing Late-Onset AD Models Using Spatial Whole Transcriptome Analysis – AGBT 2021
Smarca4-deficient lung cancers display a metastatic-like cell state and a distinct cell-of-origin – AGBT 2021
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
Synovial sarcoma (SyS) is an aggressive neoplasm driven by the SS18-SSX fusion, and is characterized by low T cell infiltration. Here, we studied the cancer-immune interplay in SyS using an integrative approach that combines single-cell RNA sequencing (scRNA-seq), spatial profiling and genetic and pharmacological perturbations.
The spatial landscape of lung pathology during COVID-19 progression
Recent studies have provided insights into the pathology and immune response to coronavirus disease 2019 (COVID-19)1–8. However, thorough interrogation of the interplay between infected cells and the immune system at sites of infection is lacking.
Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection
The relationship of SARS-CoV-2 pulmonary infection and severity of disease is not fully understood. Here we show analysis of autopsy specimens from 24 patients who succumbed to SARS-CoV-2 infection using a combination of different RNA and protein analytical platforms to characterize inter-patient and intra-patient heterogeneity of pulmonary virus infection.